Financials

News Ideas Discussions Technicals Forecast Seasonals

4IPH fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to INNATE PHARMA operating, investing, and financing activities

4IPH free cash flow for H1 24 is 2.75 M EUR. For 2023, 4IPH free cash flow was -32.91 M EUR and operating cash flow was -32.56 M EUR.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—